Clinical significance of P16INK4A and retinoblastoma proteins in non-small-cell lung carcinoma

Lung Cancer

Volumn 38, Issue 3, 2002, Pages 253-260

  Akin, Hale ^a   Yilmazbayhan, Dilek ^a   Kiliçaslan, Zeki ^a   Dilege, Şükrü ^a   Doğan, öner ^a   Toker, Alper ^a   Kalayci, Göksel ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Lung carcinoma; Non small cell; p16; pRb

Indexed keywords

FORMALDEHYDE; PARAFFIN; PROTEIN P16; RETINOBLASTOMA PROTEIN; PROTEIN P16INK4A;

ADULT; AGE; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PARAMETER; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DETERMINATION; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; SEX DIFFERENCE; TISSUE FIXATION; ADENOCARCINOMA; CHI SQUARE DISTRIBUTION; DISEASE COURSE; ENZYME IMMUNOASSAY; LUNG TUMOR; METABOLISM; MIDDLE AGED; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; SQUAMOUS CELL CARCINOMA;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CHI-SQUARE DISTRIBUTION; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RETINOBLASTOMA PROTEIN;

EID: 0036890048     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-5002(02)00301-X     Document Type: Article

References (27)

1. Flehinger B.J., Kimmel M., Melamed M.R. The effect of surgical treatment on survival from early lung cancer. Chest. 101:1992;1013-1018.
2. Strauss G.M. Prognostic markers in resectable non-small cell lung cancer. Hematol. Oncol. Clin. North Am. 11:(3):1997;409-434.
3. Fong K.M., Sekido Y., Minna J.D. Molecular pathogenesis of lung cancer. J. Thorac. Cardiovasc. Surg. 118:1999;1136-1152.
4. Locher J. Tumour suppressor genes and the practice of surgical pathology. Hum. Pathol. 26:1995;359-361.
5. Bunn P.A., Soriano A., Johnson G. New therapeutic strategies for lung cancer. Biology and molecular biology come of age. Cancer. 117:(suppl 1):2000;163s-168s.
6. Kohno T., Yokota J. How many tumour suppressor genes are involved in human lung carcinogenesis. Carcinogenesis. 20:1999;1403-1410.
7. Michalides R.J.A.M. Cell cycle regulators: mechanisms and their role in etiology, prognosis, and treatment of cancer. J. Clin. Pathol. 52:1999;555-568.
8. Claudio PP, Giordano A, RB1 and RB2. In: Pass HI, Mitchell JB, Jhonson DH, Turrisi AT, Minna JD, editor. Second ed. Lippincott Williams & Wilkins, 2000. p. 133-155.
9. INK4A, and cycline D1 in non-small cell lung carcinoma and their clinical significance. J. Pathol. 188:1999;351-360.
10. ink4a, and p53 expression with 3p loss of heterozygosity, other genetic abnormalities, and clinical features in 103 primary non-small cell lung cancers. Clin. Cancer Res. 5:1999;799-800.
11. INK4a expression in resected non-small cell lung tumours. Cancer Res. 56:1996;3415-3420.
12. INK4A is an early event in lung cancer and a potential biomarke for early diagnosis. Proc. Natl. Acad. Sci. USA. 95:1998;11891-11896.
13. INK4A and retinoblastoma protein status in non-small cell lung cancer: potential synergistic effect with altered p53 protein on proliferative activity. Cancer Res. 56:1996;5557-5562.
14. Gorgoulis V.G., Zacharatos P., Kotsinas A., et al. Alterations of the p16-pRb pathway and the chromosome locus 9p21-22 in non-small-cell lung carcinomas. Am. J. Pathol. 153:1998;1749-1765.
15. Geradts J., Kratzke R.A., Niehans G.A., et al. Immunohistochemical detection of the cyclin-dependent kinase inhibitor 2/multiple tumour suppressor gene 1 (CDKN2/MTS1) product p16INK4A in archival human solid tumours: correlation with retinoblastoma protein expression. Cancer Res. 55:1995;6006-6011.
16. Spanakis N.E., Gorgoulis V., Mariatos G., et al. Aberrant p16 expression is correlated with hemizygous deletions at the 9p21-22 chromosome region in non-small cell lung carcinomas. Anticancer Res. 19:1999;1893-1900.
17. Travis W.D., Colby T.V., Corrin B., et al. Histological Typing of Lung and Pleural Tumours. 3rd ed. 1999;Springer.
18. Mountain C.F. Revisions in the international system for staging lung cancer. Chest. 111:1997;1710-1717.
19. Radhi J.M. Malignant melanoma arising from nevi, p53, p16, and bcl-2 expression. J. Cutan. Med. Surg. 3:1999;293-297.
20. Yuan J., Knorr J., Altmannsberger M., et al. Expression of p16 and lack of pRB in primary small cell lung cancer. J. Pathol. 189:1999;358-362.
21. INK4 expression in nonsmall cell lung carcinoma. Cancer. 80:1997;389-395.
22. INK4A, retinoblastoma and p53 proteins for the prognosis of non-small cell lung cancers. Br. J. Cancer. 81:1999;696-701.
23. Chen J.-T., Chen Y.-C., Chen C.-Y., et al. Loss of p16 and/or pRb protein expression in NSCLC, An immunohistochemical and prognostic study. Lung Cancer. 31:2001;163-170.
24. Gugger M., Kappeler A., Vonlanthen S., et al. Alterations of cell cycle regulators are less frequent in advanced non-small cell lung cancer than in resectable tumours. Lung Cancer. 33:2001;229-239.
25. Sakaguchi M., Fujii Y., Rubins J.B., et al. Inversely correlated expression of p16 Rb protein in non-small cell lung cancers: an immunohistochemical study. Int. J. Cancer. 65:1996;442-445.
26. Serrano M., Hannon G.J., Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature. 366:1993;704-707.
27. Dosaka-Akita H., Fujino M., Harada M., et al. Altered retinoblastoma protein expression in nonsmall cell lung cancer. Cancer. 79:1997;1329-1337.